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Abstract
Inflammatory breast cancer (IBC) is the most aggressive
form of breast cancer, and here, we examined in vitro the
interactions between the human IBC cell line SUM149
and U937 human naive monocytes. We found an altered
morphology, enhanced invasiveness and proteolytic
activity of SUM149 cells when cultured with U937 cells
or in U937-conditioned media (U937-CM). Increases in
expression and activity of the cysteine protease cathep-
sin B and expression of caveolin-1 were also detected in
SUM149 cells grown in U937-CM, thus suggesting a
contribution of these proteins to the augmented invasion
through and proteolysis of the extracellular matrix by the
IBC cells.
Keywords: cathepsin B; caveolin-1; co-culture;
extracellular matrix; proteolysis.
Inflammatory breast cancer (IBC) is the most lethal form
of primary breast cancer and disproportionately targets
younger women. Although IBC accounts for up to 5% of
all breast cancer cases in the United States, its incidence
is significantly higher among African-American women
(10.1%) and women of Northern African countries
(1–10%) (Omar et al., 2003; Labidi et al., 2008). Surveil-
lance Epidemiology and End Results (SEER) analysis
revealed that the incidence of IBC increased approxi-
mately 2.5-fold between 1990 and 1997, whereas the
incidence of non-inflammatory locally advanced breast
cancer (LABC) decreased by approximately 2.5-fold
(Hance et al., 2005). Despite multi-modal treatment pro-
tocols utilizing neoadjuvant chemotherapy, mastectomy
followed by adjuvant chemotherapy and accelerated
hyperfractionated radiation, the 3-year survival rate for
patients with IBC is merely 40% as compared to 85%
for non-IBC patients (Lerebours et al., 2005). Dismal sur-
vival rates for IBC patients are attributed to the rapid pro-
gression, significant lymph node involvement and distant
metastasis of the disease at the time of diagnosis. More-
over, a palpable tumor mass is not usually present in IBC,
thus making diagnosis challenging using conventional
mammography or breast ultrasound (Cariati et al., 2005;
Hance et al., 2005).
Clinically, IBC is a form of LABC that is of ductal cel-
lular origin and has distinct features that include rapid
onset, erythema, edema of the breast and a ‘peau
d’orange’ appearance of the skin. IBC tumors are highly
proliferative, angiogenic and invasive, particularly into
dermal lymphatic vessels where they form tumor emboli
(Van Laere et al., 2006). Lymphatic obstruction by these
tumor emboli underlies the inflammatory nature of the
disease (Giordano and Hortobagyi, 2003; Lerebours et
al., 2005). While there are recent efforts to study IBC, the
molecular and genetic nature of this disease remains
poorly understood. A number of prognostic markers for
IBC, including HER2/neu amplification/overexpression
and lack of estrogen receptor, have been identified (Dela-
rue et al., 1981). Overexpression of genes, such as epi-
dermal growth factor receptor (egfr), rhoC and e-
cadherin, and the loss of expression of genes, including
libc (lost in inflammatory breast cancer) and wisp3 (Wnt-
1-inducible secreted protein 3), highly correlate with IBC
tumorigenesis (van Golen et al., 1999; Kleer et al., 2005).
Unfortunately, these markers do not distinguish IBC from
non-IBC and fail to explain their distinct biology (Bieche
et al., 2004).
Along with IBC cells, investigators are now profiling
stromal cells associated with IBC. For example, fibro-
blasts associated with breast cancer can induce ‘genetic
alterations’ related to poor prognosis of the disease
(Radisky and Radisky, 2007). As well, monocytes that
infiltrate into the breast tissue proliferate and differentiate
into tumor-associated macrophages, a cell type for which
a strong association has been made with poor prognosis
of breast cancer (Leek et al., 1996). Advances in intravital
imaging technology have provided new insights into how
migration and invasion of breast cancer cells are regu-
lated by elements of the local microenvironment, includ-
ing the presence of macrophages (Condeelis and Pollard,
2006). For example, toll-like receptors, which are highly
expressed by myelomonocytic cells, including circulating
monocytes, macrophages and dendritic cells, in
response to microbial or viral infections (Nagai et al.,
2006), are also overexpressed in IBC patient tissue (Van
Laere et al., 2005). These receptors are also upstream
activators of NF-kB transcription, and in breast cancer
NF-kB promotes invasion by increasing cell motility and
migration (Huber et al., 2004). Thus, these data support
our hypothesis that inflammatory cells, such as mono-
cytes enhance IBC tumorigenesis, malignancy and lym-
phovascular invasion (Schoppmann et al., 2006).
Previously, we investigated the interactions between
non-IBC cell lines (MDA-MB-231 and BT20) and naive or
tumor-educated U937 human monocytes (Sameni et al.,
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Figure 1 U937 cells affect the morphogenesis of IBC cells.
SUM149 cells (provided by Dr. Stephen P. Ethier, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, USA) were
grown for 24 h in rBM (Cultrex, Trevigen, Gaithersburg, MD, USA) overlay cultures (adapted from Debnath et al., 2003) in complete
media wHam’s F12 media with 5% FBS (Sigma, St. Louis, MO, USA)x (A), in co-culture (ratio 3:1) with U937-cells (American Type
Culture Collection, Manassas, VA, USA) pre-labeled with CellTracker Orange (Invitrogen, Carlsbad, CA, USA) (red) (B), or in U937-
CM (serum-free Ham’s F12 media conditioned by U937 cells for 24 h) (C). Confocal microscopy was performed in the Microscopy
and Imaging Resources Laboratory (MIRL) with a Zeiss LSM 510 META NLO microscope (Carl Zeiss, Thornwood, NY, USA). Images
are representative of at least three experiments. Bars, 100 mm.
Figure 2 Conditioned medium from U937 cells enhances the
invasion of IBC cells.
Equal numbers of SUM149 cells were seeded and incubated for
24 h on rBM-coated filters within invasion chambers (BD Bio-
science, San Jose, CA, USA) (Cavallo-Medved et al., 2005). The
stimulants for invasion were either complete media (Ham’s F12
media with 5% FBS) (A) or U937-CM (B). Images of three rep-
resentative fields were taken at 100= magnification. SUM149
cells that had invaded through the filters were stained using Diff-
Quik Stain Set (Dade Behring, Newark, DE, USA), counted in
three random microscopic fields and expressed as number of
cells that had invaded (C). Results from three independent
experiments are expressed as mean"standard deviation (SD).
*Represents a p-value-0.05, as determined by Student’s t-test.
Confocal microscopy was performed in MIRL with a Zeiss LSM
510 META NLO microscope (Carl Zeiss, Thornwood, NY, USA).
Figure 3 Functional imaging of proteolysis by SUM149 cells
grown alone or in co-culture with U937 cells.
In a live cell proteolysis assay, SUM149 cells were grown on
rBM (Cultrex) mixed with 25 mg/ml of quenched fluorescent
(DQ)-collagen IV substrate (Invitrogen Life Technologies, Carls-
bad, CA, USA) and overlaid with 2% rBM for 24 h either alone
(A) or in co-culture (ratio 3:1) with U937 cells pre-labeled with
CellTracker Orange (red) (B) (Sameni et al., 2003). Degradation
of DQ-collagen IV (green fluorescence) by live SUM149 cells
alone and in co-culture with U937 cells was observed with a
Zeiss LSM 510 META NLO microscope (Carl Zeiss) using a 40=
water immersion objective. Images represent a single confocal
slice at the equatorial plane. Nuclei were stained with DAPI (blue)
(Invitrogen Life Technologies). Results are representative of at
least three independent experiments. Bars, 10 mm.
2003; Mohamed and Sloane, unpublished data). In these
studies, breast cancer cells were either co-cultured with
naive or tumor-educated monocytes or treated with the
conditioned media of these cells. These interactions
result in increased proteolytic activity, extracellular matrix
(ECM) degradation and invasiveness of the breast tumor
cells. Moreover, using cytokine antibody arrays, we iden-
tified the major cytokines and proteases potentially
involved in the cross-talk between these breast tumor
cells and human monocytes (Mohamed and Sloane,
unpublished data). Here, we studied the response of the
human IBC cell line SUM149 to U937 human monocytes.
Using confocal microscopy, we assessed the morphol-
ogy of SUM149 cells grown on a reconstituted basement
membrane (rBM) and overlaid with 2% rBM, a method
adapted from one used by Brugge and colleagues to
analyze morphogenesis and oncogenesis of breast epi-
thelial cells (Debnath et al., 2003). We found that
SUM149 cells grown alone on rBM for 24 h formed sphe-
roid-like structures (Figure 1A). When these cells were
grown in co-culture with U937 (Figure 1B) or in media
conditioned by U937 cells (U937-CM; Figure 1C), we
observed in both cases a morphological change from
spheroidal to branching-like structures. In addition,
U937-CM enhanced the invasion of SUM149 cells
through rBM-coated filters as compared to control media
(Ham’s F-12 media plus 5% fetal bovine serum, FBS)
(Figure 2). Our data suggest that secretions from U937
cells stimulate morphological changes in SUM149 cells
and promote their invasion.
Since invasion of tumor cells is linked to degradation
of ECM proteins, we examined the effects of monocytes
on degradation of the ECM protein type IV collagen by
SUM149 cells. In a live cell proteolysis assay that uses a
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Figure 4 Conditioned media from U937 cells increases the levels and activity of cathepsin B in SUM149 cells.
To specifically see the effect of U937 secretions on the expression of cathepsin B in SUM149 without the influence of rBM, SUM149
cells were grown on plastic for 48 h in complete media alone (Ham’s F12 media with 5% FBS) (lane 1) or with U937-CM (lane 2),
washed several times with phosphate buffered saline and incubated overnight in serum-free medium. Cells were solubilized in lysis
buffer w250 mM sucrose, 25 mM MES pH 7.5, 1 mM EDTA, 0.1% Triton X-100 (Sigma)x and cell lysates were subjected to 12% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotted with polyclonal antibodies against cathepsin B
(Moin et al., 1992) and b-actin (Sigma) as a loading control. Cathepsin B forms observed are the proenzyme (43/46 kDa), an inter-
mediate form (38 kDa), single chain mature enzyme (31 kDa) and the heavy chain of double chain mature enzyme (25/26 kDa heavy
chain) (A). Immunoblots are representative of at least three independent experiments. Cathepsin B activity in cell lysates was deter-
mined using a fluorogenic enzymatic assay that employs 100 mM Z-Arg-Arg-NHMec (Bachem, Torrance, CA, USA), which under the
conditions of this assay is a selective substrate for cathepsin B (Linebaugh et al., 1999), in the presence and absence of 10 mM
CA074 (Peptide Institute, Louisville, KY, USA), a highly selective cathepsin B inhibitor (Linebaugh et al., 1999; Montaser et al., 2002).
Cathepsin B activity in the cell lysates of SUM149 cells grown in complete media (white bar) and in U937-CM (black bars) is expressed
as pmol/min/mg DNA (B). Pepsin (Roche, Indianapolis, IN, USA)-activated cathepsin B activity was also measured in the conditioned
media of both SUM149 (positive control) and U937 cells using 100 mM Z-Arg-Arg substrate (Linebaugh et al., 1999) and expressed
as pmol/min/mg DNA (C). The insert panel shows SUM149 (lane 1) and U937 (lane 2) conditioned media subjected to SDS-PAGE
and immunoblotting using polyclonal cathepsin B antibody. Graphs are representative of at least three independent experiments and
presented as mean"S.D. *Indicates a p-value -0.05, as determined by Student’s t-test. Intracellular immunostaining for cathepsin
B (green) was performed on SUM149 cells grown on glass coverslips in complete media (Ham’s F12 medium with 5% FBS) (D) or
in U937-CM (E). Cells were incubated in the presence of saponin (Sigma) with a primary polyclonal antibody against cathepsin B
followed by FITC-conjugated affinity-purified donkey anti-rabbit IgG (Jackson ImmunoResearch, West Grove, PA, USA) plus 5%
normal donkey serum (Cavallo-Medved et al., 2005). Confocal microscopy was performed in MIRL with a Zeiss LSM 510 META NLO
microscope (Carl Zeiss) using a 63= lens under oil immersion. On glass coverslips, IBC cells form a monolayer, thus differing in
morphology from those illustrated in Figure 1 where they are grown in a three-dimensional rBM culture. These images are represen-
tative of three experiments. Nuclei were stained with DAPI (blue). Bars, 10 mm.
dye-quenched fluorescent (DQ)-collagen IV substrate,
the most abundant collagen type found in basement
membrane, mixed with rBM (Sameni et al., 2003), we
found increased DQ-collagen IV degradation (observed
as green fluorescence) when SUM149 cells were co-cul-
tured with U937 cells as compared to when they were
grown alone (Figure 3). The increase in DQ-collagen IV
degradation correlates with the branched morphology of
SUM149 cells induced by co-culture with U937 cells and
the enhanced invasiveness of SUM149 cells in response
to U937-CM.
As a first step in identifying which enzymes are
involved in ECM degradation, we examined the expres-
sion and activity of a lysosomal cysteine protease,
cathepsin B, in SUM149 cells. Cathepsin B is involved in
various steps of tumor progression, including digestion
of adhesion molecules, degradation of extracellular
matrix, motility, angiogenesis, invasion and metastasis
(Ren and Sloane, 1996; Mohamed and Sloane, 2006).
Moreover, cathepsin B has been suggested to be a bio-
logical marker for breast tumors (Wulfkuhle et al., 2002)
and has been implicated in breast tumor cell invasion
(Lah et al., 2000; Premzl et al., 2003). In a recent study,
a nanoparticulate delivery system composed of poly(D,L-
lactide-coglycolide) nanoparticles, anti-cytokeratin
monoclonal IgG and cystatin was used to penetrate
1120 M.M. Mohamed et al.
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Figure 5 Conditioned medium of U937 cells increases the
expression of caveolin in SUM149 cells.
Cell lysates of SUM149 cells grown on plastic for 48 h in com-
plete media alone (Ham’s F12 medium with 5% FBS) (lane 1) or
with U937-CM (lane 2) were subjected to 12% SDS-PAGE and
immunoblotted with polyclonal antibodies against caveolin (BD
Biosciences, San Jose, CA, USA) and b-actin (loading control).
Results are representative of at least three independent
experiments.
breast cancer cells and inhibit intracellular cathepsin B
activity, respectively, thereby reducing the invasiveness
of these tumor cells in vitro (Obermajer et al., 2007). Here,
in immunoblotting and fluorogenic enzymatic assays
(Linebaugh et al., 1999), we detected increases in
cathepsin B expression and activity in SUM149 cells
grown in U937-CM (Figure 4). In these experiments,
SUM149 cells were grown on plastic to examine the
direct effects of U937-CM (i.e., in the absence of rBM)
on these cells. CA074, a highly selective cathepsin B
inhibitor (Montaser et al., 2002), was used to verify
cathepsin B activity detected in the enzymatic assay (Fig-
ure 4B). Moreover, both immunoblotting and enzymatic
assays verified the absence of cathepsin B in U937-CM
as compared to conditioned media of SUM149 cells
(SUM149-CM) used as a positive control (Figure 4C). This
indicated that the increase in cathepsin B expression and
activity detected in SUM149 cells grown in U937-CM
was not a result of uptake of cathepsin B secreted from
U937 cells (Figure 4C). Thus, the upregulation in cathep-
sin B expression and activity in SUM149 cells would be
consistent with this enzyme contributing to the increases
in both ECM degradation and invasion by these cells.
Furthermore, we analyzed subcellular distribution of
cathepsin B in SUM149 grown in coverslips in the
absence and presence of U937-CM (Figure 4D and E,
respectively). Increased expression of cathepsin B, local-
ized in vesicles in the perinuclear region, was detected
in SUM149 grown in U937-CM (Figure 4E). Analyses of
other proteases that may contribute to increases in ECM
degradation and invasion are ongoing.
Caveolin-1, the structural protein of lipid raft caveolae,
was initially reported to act as a breast tumor suppressor
(Bouras et al., 2004); however, recent studies have clas-
sified caveolin-1 and -2 as biomarkers for the basal-like
phenotype in the breast carcinoma subgroup (Sagara et
al., 2004; Pinilla et al., 2006) that includes IBC (Perou et
al., 2000). Upregulation of caveolin-1 has been observed
in other malignancies, such as colon, prostate and pan-
creatic cancers (Yang et al., 1998; Fine et al., 2001;
Suzuoki et al., 2002), particularly in the metastatic stage
of the disease. In IBC cell lines and patient tumor tissues,
overexpression of caveolin-1 and -2 correlates with
increased expression of RhoC, implicating these proteins
in the aggressive phenotype of IBC (Van den Eynden et
al., 2006). We have previously suggested that caveolin-1
and caveolae contribute to tumor invasion by compart-
mentalizing several cell surface proteases involved in
ECM degradation (Cavallo-Medved et al., 2005), and our
ongoing studies using patient samples will elucidate the
contribution of caveolae-associated proteases in the
metastatic phenotype of IBC. We have identified cell sur-
face cathepsin B associated with caveolae of human,
colorectal carcinoma cells (Cavallo-Medved et al., 2003).
Moreover, we found that downregulation of caveolin-1
alters trafficking of cathepsin B to caveolae and decreas-
es secretion of this enzyme, thereby reducing ECM deg-
radation by and invasion of these cells (Cavallo-Medved
et al., 2005). Here, we found that in SUM149 cells grown
in U937-CM, caveolin-1 expression was significantly
increased compared to control SUM149 cells (Figure 5).
These results correlate with the overexpression of
cathepsin B in SUM149 cells under these conditions and
may suggest an increase in the association of cathepsin
B with caveolae.
Our study supports the hypothesis that interaction of
monocytes with IBC cells stimulates the invasiveness of
IBC cells. We speculate that this is the result of enhanced
cell surface activity of the cysteine protease cathepsin B
in IBC cells. The increased invasion and proteolysis in
the IBC cells are accompanied by: (i) increased expres-
sion and activity of cathepsin B, and (ii) increased
expression of caveolin-1, caveolae being a site for local-
ization of cathepsin B on the tumor cell surface.
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